Senti Bio License for Development and Commercialization of Next Generation Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like tyrosine kinase 3 (FLT3) Expressing Cancers

On April 19, 2019, HealthGap, Knowledge Ecology International, Public Citizen, Social Security Works and the Union for Affordable Cancer Treatment filed comments on a proposed license on National Cancer Institute patented inventions to Senti Bio, for a next generation CAR… Continue Reading

UNDP, Unitaid, and WHO caught in Big Pharma’s crosshairs

PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading

WTO TRIPS Council: Submission of the European Union, the United States and 9 other WTO members on Public-Private Collaborations in Innovation

On 8 February 2019, the World Trade Organization (WTO) published a submission (IP/C/W/652) by Australia; Canada; Chile; The European Union; Hong Kong, China; Japan; the Republic of Korea; Singapore; Switzerland; Chinese Taipei; and the United States to the TRIPS Council… Continue Reading

WHO Cancer Report – Key findings

On 18 December 2018, the World Health Organization (WHO) published a “Technical report on Pricing of cancer medicines and its impacts” (hereinafter referred to as the “WHO Cancer Report”). The mandate for the WHO Cancer Report emanates from operative paragraph… Continue Reading